Results 221 to 230 of about 331,825 (303)

Patient‐derived organoid‐immune co‐cultures integrated with multi‐omics reveal immunotherapy resistance mechanisms in urothelial carcinoma

iMeta, EarlyView.
Immunotherapy resistance presents a formidable challenge in tumor biology. While fibroblast growth factor receptor 3 (FGFR3) serves as a pivotal oncogenic driver in a multitude of cancers, the exploration of its role in immune checkpoint inhibitor (ICI) resistance remains scarce, thus impeding a deeper understanding of the tumor immune microenvironment
Shan Jiang, Yuxuan Song, Yun Peng, Ran Yan, Yunze Niu, Baoqiang Chen, Jiaxing Lin, Jilin Wu, Shixiang Wang, Yiqing Du, Caipeng Qin, Yihan Lin, Tao Xu   +12 more
wiley   +1 more source

Overexpression of MFAP4 inhibits the proliferation, migration, and invasion of bladder cancer cells. [PDF]

Discov Oncol
Zhang W, Dai L, Luo M, Shi H.
europepmc   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

Knowledge mapping of photodynamic therapy in bladder cancer: a bibliometric analysis (2000-2025). [PDF]

Transl Androl Urol
Yuan J, Xing S, Sun W, Zeng S, Li Y, Xu Z, Zhang Y, Liu X, Xing J, Liu Q.   +9 more
europepmc   +1 more source

Tiny carriers, big impact: How Fusobacterium nucleatum extracellular vesicles drive oral diseases and beyond

Interdisciplinary Medicine, EarlyView.
This review explores how Fusobacterium nucleatum extracellular vesicles drive local oral diseases and distal pathologies via sophisticated cross‐compartment cross talk. It highlights the transformative potential of these “tiny carriers” as next‐generation molecular intermediaries for advanced health monitoring and innovative bio‐interventions by ...
Rongyang Ma, Jiahui Huang, Yitong Chen, Haoxuan Wang, Hang Zou, Wanghong Zhao, Zilong Deng   +6 more
wiley   +1 more source

Bladder Cancer Immunotherapy in 2025: ALBAN, CREST, POTOMAC, and the Winner Is BCG! [PDF]

Int Braz J Urol
Reis LO.
europepmc   +1 more source

Implantable drug delivery system: Frontiers of medicine‐engineering interdisciplinary

Interdisciplinary Medicine, EarlyView.
This review systematically summarizes the driving mechanisms of implantable on‐demand drug delivery systems (IDDS), including endogenous, exogenous, and closed‐loop strategies. It highlights the pivotal roles of flexible electronics and miniaturization in enhancing the tissue conformity and spatial adaptability.
Yu Zeng, Rongtai Su, Manyu Zhao, Xin Song, Ran Liu, Yuhao Zhou, Chaojuan Yang, Yanli Jiao, Xiao‐Wei Xiang, Lingqian Chang   +9 more
wiley   +1 more source

FAM107A loss facilitates TTK‐OPTN‐mediated mitophagy to drive docetaxel resistance in castration‐resistant prostate cancer

Interdisciplinary Medicine, EarlyView.
In the progression of docetaxel resistance, downregulation of FAM107A releases its transcriptional repression of TTK, leading to TTK upregulation. TTK enhances the interaction and phosphorylation of OPTN. This activates mitophagy in tumor cells, facilitates clearance of damaged mitochondria, reduces intracellular reactive oxygen species accumulation ...
Yishan Zhang, Fan Zou, Mingdong Wang, Chenyue Wu, Yingwei Xie, Yongjun Quan, Wei Yan, Yupeng Zheng, Lianhua Li, Yuexin Liu, Jian Yu, Hao Ping   +11 more
wiley   +1 more source

Periocular Pigmentation After Gemcitabine Monotherapy for Bladder Cancer: A Rare Case Report. [PDF]

Clin Case Rep
Juan L, Weiping C.
europepmc   +1 more source

Challenging Cases in Urothelial Cancer

Bladder Cancer, 2018
Mark S. Soloway
doaj   +1 more source